Clinical Trial

Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Phase 1 randomized, double-blind, placebo-controlled trial to evaluate safety, tolerability, pharmacokinetics (PK) and immunogenicity of IDB-011 following intramuscular (IM )administration of single ascending doses to healthy adult participants.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-07.
Status change: Recruiting → Active, Not Recruiting 2026-03-23
Trial Details
NCT Number NCT06925919
Lead Sponsor IDBiologics, Inc.
Collaborators: Joint Program Executive Office Chemical, Biological, Radiological, and Nuclear Defense Enabling Biotechnologies
Conditions Rift Valley Fever
Enrollment 40 participants
Start Date 2025-04-02
Primary Completion 2026-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-03-25